Google Übersetzer
Tarsus Pharmaceuticals, Inc.
About
60.00USD-0.06 -0.10%
Closed • Updated at 15:06 GMT+00:00Market Cap$2.58B
Volume48.1K
Beta0.21
RSI40.73
Gross Margin93.48%
Tarsus Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 6 2026
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Apr 29 2026
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Mar 31 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
Mar 23 2026
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Feb 23 2026
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
Recent Videos
75.Medical Maverick : Exploring Pharma Innovation with Dr. Arthur Chan
May 11, 2026
The Burden of Demodex Blepharitis (DB) with Prof. Béatrice Cochener-Lamard | Tarsus
May 11, 2026
The Burden of Demodex Blepharitis with Dr. med. Stefanie Schmickler | Tarsus
Apr 29, 2026
Tarsus Pharmaceuticals: Commercial Inflection and Pipeline Expansion Analysis #TARS TARS $TARS
Apr 05, 2026
Community Chat
Ask AI
Try asking